Bruton's tyrosine kinase as anti-cancer drug target
US10421820B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Sep 6, 2016 |
| Grant date | Sep 24, 2019 |
| Priority date | — |
| Expiry date | Sep 6, 2036 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/9121
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Receptor protein kinases (RPTKs) transmit extracellular signals across the plasma membrane to cytosolic proteins, stimulating formation of complexes that regulate key cellular functions. Over half of the known tyrosine kinases are implicated in human cancers and are therefore highly promising drug targets. A large-scale loss-of-function analysis of tyrosine kinases using RNA interference in the clinically relevant Erb-B2 positive, BT474 breast cancer cell line showed that Bruton's tyrosine kinase (BTK), a cytosolic, non-receptor tyrosine kinase that has been extensively studied for its role in B cell development, is required, in altered form, for BT474 breast cancer survival. This alternative form contains an amino-terminal extension that is also present in tumorigenic breast cells at significantly higher levels than in normal breast cells. Thus, embodiments of the invention find application in the field of cancer therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.